BACKGROUND: The phosphatidylinositol 3-kinase (PI3K)/phosphatase and tensin homolog (PTEN)/v-akt murine thymoma viral oncogene homolog (Akt)/mammalian target of rapamycin (mTOR) pathway is central in the transmission of growth regulatory signals originating from cell surface receptors. OBJECTIVE: This review discusses how mutations occur that result in elevated expression the PI3K/PTEN/Akt/mTOR pathway and lead to malignant transformation, and how effective targeting of this pathway may result in suppression of abnormal growth of cancer cells. METHODS: We searched the literature for articles which dealt with altered expression of this pathway in various cancers including: hematopoietic, melanoma, non-small cell lung, pancreatic, endometrial and ovarian, breast, prostate and hepatocellular. RESULTS/CONCLUSIONS: The PI3K/PTEN/Akt/mTOR pathway is frequently aberrantly regulated in various cancers and targeting this pathway with small molecule inhibitors and may result in novel, more effective anticancer therapies.
|Titolo:||Akt as a therapeutic target in cancer|
|Data di pubblicazione:||2008|
|Citazione:||Akt as a therapeutic target in cancer / STEELMAN LS; STADELMAN KM; CHAPPELL WH; HORN S; BÄSECKE J; CERVELLO M; NICOLETTI F; LIBRA M; STIVALA F; MARTELLI AM; MCCUBREY JA. - In: EXPERT OPINION ON THERAPEUTIC TARGETS. - ISSN 1472-8222. - 12:9(2008), pp. 1139-1165.|
|Appare nelle tipologie:||1.1 Articolo in rivista|